fibrin, MSCs, stem cells, heart failure, Antoni Bayes-Genis, umbilical cord

To date, the only definitive treatment for heart failure — an organ transplant — is hampered by both the limited number of organ donors and the potential for the patient's body to reject the new heart. However, findings of a study published in STEM CELLS: Translational Medicine demonstrate the promise in regenerating cardiac tissue using engineered patches made up of a mixture of fibrin and mesenchymal stem cells (MSCs) derived from human umbilical cord blood.

Scott & White Memorial — Temple for the first time implanted a new miniaturized, wireless monitoring sensor to help manage heart failure (HF). Scott & White Memorial is one of six hospitals in Texas and the first hospital in the Baylor Scott & White Health system to offer the device.

Texas Children's Hospital successfully separated Knatalye Hope and Adeline Faith Mata in late February, completing one of the most complex conjoined twins separations ever. The procedure took months of planning, and Toshiba's Aquilion ONE CT system played a crucial role in determining the feasibility of separating the twins and producing images that helped radiologists build detailed 3-D models of the organs.

Philips announced the introduction of Lumify, its first app-based ultrasound solution that will extend the reach of ultrasound applications across the health continuum using mobile technology. The technology was unveiled at the Social Media and Critical Care (SMACC) conference, June 23-26, in Chicago.

InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at the EuroPCR conference, May 22 in Paris. The study was lead by principle investigator Prof. Piotr Musialek.

Results from a clinical trial evaluating the Micra transcatheter pacing system (TPS), the world’s smallest pacemaker, were presented at the Heart Rhythm Society’s 36th annual scientific sessions in May. The device was shown to meet its initial safety and performance measures, as 100 percent of the first 140 patients who received it experienced a successful implant procedure. The study was conducted at the Minneapolis Heart Institute Foundation.

defibrillators, older heart patients, Duke Medicine study, Tracy Wang

Heart attack patients age 65 and older who have reduced heart function might still benefit from implanted defibrillators, according to a Duke Medicine study published in the Journal of the American Medical Association. But fewer than 1 in 10 eligible patients actually get a defibrillator within a year of their heart attacks, the study found.

Medtronic plc announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the recapturable, self-expanding CoreValve Evolut R System. The first-and-only recapturable and repositionable device available in the United States, the Evolut R System is approved for transcatheter aortic valve replacement (TAVR) in severe aortic stenosis patients who are at high or extreme risk for surgery. Untreated, aortic valve stenosis can lead to serious heart problems including heart failure and even death.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now